ADMA Q1 2025 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$115M+40.2% YoY

Gross Profit

$61M53.2% margin

Operating Income

$35M30.4% margin

Net Income

$27M23.4% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

-2.3%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$24M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$511M

Total Liabilities

$137M

Stockholders' Equity

$373M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$115M	$82M	+40.2%
Gross Profit	$61M	$39M	+56.2%
Operating Income	$35M	$22M	+59.9%
Net Income	$27M	$18M	+51.1%

Geographic Segments

UNITED STATES

$111M96%

Non-US

$4M4%